Table 6. Cost-effectiveness benchmarks in oncology.
| Cancer setting | Life-expectancy gain (months) | Cost per life year gained | |
|---|---|---|---|
| Capecitabine vs 5-FU/LV | Colon adjuvant | 8.7a | Dominantb |
| FOLFIRI vs 5-FU/LVc | Colorectal metastatic | 2.6 | £29 000 |
| AT vs ACc | Breast metastatic | NA | £19 000 |
| CMF vs observationd | Breast adjuvant | 3.6 | US$447 |
| Chemotherapy vs observatione | Breast adjuvant | 5.1a | US$15 400a |
NA=not available.
a
Quality-adjusted values.
b
Cost saving and more effective in terms of quality-adjusted life months.
c
National Institute for Health and Clinical Excellence.